Table 4.
Primary endpoint | N = 50 | 95% CI |
---|---|---|
Early progression (EP), n (%) | 13 (26) | (0.1, 0.4) |
Progression-free at 9 weeks (PFS9w), n (%) | 18 (36) | (0.2, 0.5) |
Neither EP nor PFS9w, n (%) | 19 (38) |
EP, disease progression or death within first 3 weeks (cycle 1).
PFS9w, alive without progression up to cycle 4 day 1 and beyond.